Cytokinetics Ispinesib Could Help Fill Gap In HER2 Negative Breast Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cytokinetics is casting a wider net with its development program for ispinesib following the targeted oncologic’s failure earlier this year in a Phase II lung cancer trial.
You may also be interested in...
Cytokinetics takes on more ispinesib duties
Cytokinetics and GlaxoSmithKline have amended their agreement relating to development of Cytokinetics' kinase spindle protein inhibitors, including the Phase II oncologic ispinesib, Cytokinetics says Nov. 27. The San Francisco biotech plans "a focused development program for ispinesib" that builds on GSK's Phase I/II efforts with the compound. During a second quarter earnings call, CEO James Sabry said the firm would cast a wider net of trials in the wake of ispinesib's Phase II failure in lung cancer (1Pharmaceutical Approvals Monthly August 2006, p. 6)...
Cytokinetics oral heart failure agent begins Phase I
After releasing top-line results of its Phase I intravenous CK-1827452 candidate to treat acute and chronic heart failure, Cytokinetics announced it will begin Phase I trials of an oral formulation of the compound. The company hopes to study the intravenous formulation in acutely decompensated heart failure patients in a hospital setting and transition them to an oral dose in an outpatient setting. Cytokinetics is already considering a sales force of 100-200 full-time employees for the drug (1Pharmaceutical Approvals Monthly August 2006, p. 6)...
Genentech Stops Avastin Ovarian Cancer Trial Enrollment After GI Perforations
Genentech is discontinuing enrollment of a Phase II study of Avastin (bevacizumab) in platinum-refractory ovarian cancer patients due to an excessively high rate of reported gastrointestinal perforations